Zogenix Ups Series B To $71M

San Diego-based Zogenix, a pharmaceuticals firm developing neuroscience disorders and pain treatments, said Monday that it has closed on $35M in a second tranche of Series B funding, bringing the firm's Series B to a total of $71M. The firm said the additional $20M came from Chicago Growth Partners. Other investors in the round, which had its first close in September, include Clarus Ventures, Domain Associates, Scale Venture Partners, Thomas, McNerney & Partners, and Abingworth Management. Dr. Arda Minocherhomjee of Chicago Growth Partners joins the firm's board along with the funding. The company said the funding will go to support the launch of the firm's SUMAVEL DosePro product. More information »